Skip to main content
. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880

Table 2.

Crude and adjusted hazard ratios for association between use of DPP-4 inhibitors and GLP-1 receptor agonists and risk of cholangiocarcinoma

Exposure* No of events Person years Incidence rate (95% CI)† Crude hazard ratio Adjusted hazard ratio (95% CI)‡
Other second or third line antidiabetic drugs 33 223 531 14.8 (10.2 to 20.7) 1.00 1.00 (reference)
DPP-4 inhibitors 27 103 362 26.1 (17.2 to 38.0) 1.70 1.77 (1.04 to 3.01)
GLP-1 receptor agonists 7 37 041 18.9 (7.6 to 38.9) 1.20 1.97 (0.83 to 4.66)

DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1.

*

Use of first line antidiabetic drugs was considered in models, but not presented in table. This group generated 38 events and 250 340 person years, yielding an incidence rate of 15.2 (95% confidence interval 10.7 to 20.8) per 100 000 person years.

Per 100 000 person years.

Adjusted for age, sex, year of cohort entry, obesity, smoking status, alcohol related disorders, Charlson comorbidity index score, inflammatory bowel disease, gallbladder disease, glycated haemoglobin (HbA1c) level, and duration of diabetes.